Correlation between 18F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer

Koo, Hye Ryoung; Park, Jeong Seon; Kang, Keon Wook; Han, Wonshik; Park, In Ae; Moon, Woo Kyung

doi:10.1007/s00330-015-3734-z

Cited by 37 publications

(35 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The macroscopic features PVC-SUV mean and SUV max showed significant correlations with MiB-1, thus confirming previous published results on their role as surrogate biomarkers of proliferation [26, 30]. Also, some intensity-based textural features were found to be correlated with MiB-1, supporting the results obtained by the macroscopic intensity-based features PVC-SUV mean and SUV max .…”

Section: Resultssupporting

confidence: 89%

Biomarkers from in vivo molecular imaging of breast cancer: pretreatment 18F-FDG PET predicts patient prognosis, and pretreatment DWI-MR predicts response to neoadjuvant chemotherapy

Gallivanone

Panzeri

Canevari

et al. 2017

Magn Reson Mater Phy

View full text Add to dashboard Cite

ObjectiveHuman cancers display intra-tumor phenotypic heterogeneity and recent research has focused on developing image processing methods extracting imaging descriptors to characterize this heterogeneity. This work assesses the role of pretreatment 18F-FDG PET and DWI-MR with respect to the prognosis and prediction of neoadjuvant chemotherapy (NAC) outcomes when image features are used to characterize primitive lesions from breast cancer (BC).Materials and methodsA retrospective protocol included 38 adult women with biopsy-proven BC. Patients underwent a pre-therapy 18F-FDG PET/CT whole-body study and a pre-therapy breast multi-parametric MR study. Patients were then referred for NAC treatment and then for surgical resection, with an evaluation of the therapy response. Segmentation methods were developed in order to identify functional volumes both on 18F-FDG PET images and ADC maps. Macroscopic and histogram features were extracted from the defined functional volumes.ResultsOur work demonstrates that macroscopic and histogram features from 18F-FDG PET are able to biologically characterize primitive BC, and define the prognosis. In addition, histogram features from ADC maps are able to predict the response to NAC.ConclusionOur work suggests that pre-treatment 18F-FDG PET and pre-treatment DWI-MR provide useful complementary information for biological characterization and NAC response prediction in BC.

show abstract

Section: Resultssupporting

confidence: 89%

Biomarkers from in vivo molecular imaging of breast cancer: pretreatment 18F-FDG PET predicts patient prognosis, and pretreatment DWI-MR predicts response to neoadjuvant chemotherapy

Gallivanone

Panzeri

Canevari

et al. 2017

Magn Reson Mater Phy

View full text Add to dashboard Cite

show abstract

“…Koo et al. found that 18 F‐FDG uptake was correlated with a high Ki‐67 index in triple‐negative breast cancer . PET based on 18 F‐FES or 89 Zr‐trastuzumab could even achieve dynamic monitoring of ER and Her‐2 status during concomitant endocrine and trastuzumab therapy.…”

Section: Molecular Imagingmentioning

confidence: 99%

Progress in the clinical detection of heterogeneity in breast cancer

et al. 2016

View full text Add to dashboard Cite

Breast cancer is currently the most common form of cancer and the second‐leading cause of death from cancer in women. Though considerable progress has been made in the treatment of breast cancer, the heterogeneity of tumors (both inter‐ and intratumor) remains a considerable diagnostic and prognostic challenge. From clinical observation to genetic mutations, the history of understanding the heterogeneity of breast cancer is lengthy and detailed. Effectively detecting heterogeneity in breast cancer is important during treatment. Various methods of depicting this heterogeneity are now available and include genetic, pathologic, and imaging analysis. These methods allow characterization of the heterogeneity of breast cancer on a genetic level, providing greater insight during the process of establishing an effective therapeutic plan. This study reviews how the understanding of tumor heterogeneity in breast cancer evolved, and further summarizes recent advances in the detection and monitoring of this heterogeneity in patients with breast cancer.

show abstract

“…195,196 Patients are injected with fluorodeoxy-dglucose, a radioactively labeled glucose analog, which is rapidly taken up by the tumor cells and then metabolically trapped after phosphorylation. [197][198][199] Research efforts are also focusing on breast cancer cells, wherein some subtypes of the disease, the cells overexpress GLUT5 rather than GLUT1, suggesting that fructose-based probes may be of value. 199,200 However, this positron emission tomography technique is expensive and the probes are very short-lived.…”

Section: Glut Expression In Relation To Diseasementioning

confidence: 99%

Structure of, and functional insight into the GLUT family of membrane transporters

Long¹,

Cheeseman²

2015

CHC

View full text Add to dashboard Cite

This review examines the development of structure and function of the human GLUT proteins, gene family hSLC2A. These proteins are essential for moving the key metabolites, glucose, galactose, and fructose in and out of cells, as well as a number of other important substrates. Despite over five decades of research, it is still not fully understood how they work at the molecular level, although the recent publication of a crystal structure of GLUT1 sug-

show abstract

Correlation between 18F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer

Abstract: • A wide range of FDG uptake reflected heterogeneity of cancer metabolism. • FDG uptake was correlated with the Ki-67 proliferation index in TNBC. • FDG uptake was correlated with tumour size in TNBC. • FDG uptake was not correlated with 'basal-like' phenotype.

Cited by 37 publications

References 39 publications

Biomarkers from in vivo molecular imaging of breast cancer: pretreatment 18F-FDG PET predicts patient prognosis, and pretreatment DWI-MR predicts response to neoadjuvant chemotherapy

Biomarkers from in vivo molecular imaging of breast cancer: pretreatment 18F-FDG PET predicts patient prognosis, and pretreatment DWI-MR predicts response to neoadjuvant chemotherapy

Progress in the clinical detection of heterogeneity in breast cancer

Structure of, and functional insight into the GLUT family of membrane transporters

Contact Info

Product

Resources

About